Tocilizumab significantly reduced 28-day mortality and length of ICU stay in patients with severe COVID-19 pneumonia and low S-spike nAb titers.

The risk of all-cause mortality among older patients with severe CAP was significantly reduced following treatment with glucocorticoids.